CTCL frequently misdiagnosed as eczema prior to the use of Dupixent in treatment
For many patients, the path to a cutaneous T-cell lymphoma diagnosis begins with years of being told they have eczema. Red patches, itching, scaling, and flare-ups that come and go all fit the picture of typical chronic dermatitis symptoms. When topical creams fail, stronger treatments are often introduced, including Dupixent. Only later do some patients discover that the underlying condition was never eczema at all. This diagnostic overlap has become a central issue in discussions about Dupixent cancer, but the challenge of misdiagnosis existed long before the medication became widely used. CTCL is rare and slow to develop, and in its earliest stages, it can look nearly identical to chronic dermatitis. Many patients cycle through years of treatment, reassured that difficult eczema can simply be hard to manage, while the lymphoma continues to evolve in ways that are not immediately recognized.
The difficulty lies in how CTCL behaves early on. According to guidance and safety discussions referenced by the U.S. Food and Drug Administration, CTCL often presents with nonspecific or ambiguous skin findings. Biopsies may come back inconclusive, particularly if taken from areas that are inflamed but not yet showing clear malignant features. Because of this, patients may receive repeated eczema diagnoses, sometimes from multiple providers, before anyone considers a different explanation. When Dupixent is introduced, the situation can become even more complex. The medication is designed to reduce inflammation and relieve itching, which may temporarily improve outward symptoms without addressing an underlying lymphoma. In some cases, rashes may change in appearance, spread, or worsen over time, eventually leading to further testing and a CTCL diagnosis. For patients, this sequence can create the impression that the drug caused the cancer, when in reality it may have revealed a condition that was already developing.
That distinction between causing disease and delaying recognition is important, but it can be difficult to explain clearly. CTCL is often described by dermatologists as a “great imitator,” meaning it can resemble other conditions for extended periods of time. Misdiagnosis is therefore not uncommon, even without advanced therapies like Dupixent. What has changed is the level of awareness. Dermatologists are increasingly encouraged to reassess long-standing eczema diagnoses that do not behave as expected. Warning signs associated with Dupixent cancer may include skin patches that fail to improve, rashes that worsen despite treatment, or symptoms accompanied by unexplained fatigue or swollen lymph nodes. The focus is now on earlier biopsy, repeat testing when needed, and closer monitoring rather than assuming treatment resistance alone. For patients, this means recognizing that a lack of improvement may signal something more than a medication issue.
Improved awareness of CTCL’s tendency to resemble eczema is likely to influence both clinical practice and ongoing regulatory monitoring. As more real-world data becomes available, patterns of delayed diagnosis are being examined alongside treatment timelines. This does not mean patients should avoid effective therapies out of concern, but it does highlight the importance of continued evaluation. Skin conditions that do not follow expected patterns deserve closer attention and, when necessary, a second opinion.